Pro-inflammatory cytokine secretion from immune and epithelial cells

Pro-inflammatory cytokine secretion from immune and epithelial cells describes a coordinated physiological response involving the release of signaling molecules like TNF-alpha, IL-1 beta, and IL-6. This process is initiated by the activation of pattern recognition receptors (PRRs) or cytokine receptors, leading to downstream signaling through pathways such as NF-kappaB and JAK/STAT (Nature Reviews Immunology, 2018). In a healthy state, these cytokines orchestrate the recruitment of immune cells to sites of infection or injury; however, dysregulated or chronic secretion is central to the pathogenesis of various inflammatory conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease (StatPearls, 2023). Epithelial cells also contribute significantly to this process, acting as both sensors of damage and producers of mediators like IL-8 and TSLP (PubMed, 2021). Pharmacological strategies to manage this process include the use of monoclonal antibodies to neutralize specific cytokines or small molecule inhibitors to disrupt the intracellular machinery responsible for their production. Because this term refers to a broad cellular phenotype rather than a discrete protein, it is categorized as a biological process rather than a single therapeutic target.

Other names

Pro-inflammatory cytokine releaseCytokine productionInflammatory mediator secretionCytokine storm

Drugs modulate this process by neutralizing specific secreted cytokines, blocking their respective receptors, or inhibiting intracellular signaling pathways such as NF-kappaB or JAK/STAT that drive cytokine gene expression and release.